5.99 USD
↘ 0.33 (5.22%)AT CLOSE (11:59 AM EDT)
Zura Bio Limited Class A Ordinary Shares
ZURANASDAQ • USD
6.06
↗ 0.06 (1.09%)
POST MARKET (AS OF 07:44 PM EDT)
Post Market
AS OF 07:44 PM EDT
6.06
↗ 0.06 (1.09%)
Market: CLOSED
Zura Bio Limited Class A Ordinary Shares (ZURA) trades at $6.00 per share. Our models show a "Strong Buy" technical signal alongside a "Neutral" fundamental rating. Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics place ZURA at a fair price relative to peers.
Technical & fundamental data as of Aug 26, 2026.
Open?$6.13
High?$6.30
Low?$5.98
Prev. Close?$6.32
Volume?1.8M
Avg. Volume?1.0M
VWAP?$6.10
Rel. Volume?1.73x
Bid / Ask
Bid?$5.14 × 100
Ask?$6.97 × 100
Spread?$1.83
Midpoint?$6.06
Valuation & Ratios
Market Cap?605.6M
Shares Out?95.8M
Float?52.0M
Float %?54.8%
P/E Ratio?N/A
P/B Ratio?3.07
EPS?-$1.22
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Employees
40
Market Cap
605.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2023-03-21
Address
4225 EXECUTIVE SQUARE
LA JOLLA, CA 92037
Phone: 858-247-0520
LA JOLLA, CA 92037
Phone: 858-247-0520
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?34
Piotroski F-Score?0/9Weak
Altman Z-Score?20.12Safe
Confidence?48%Low
Short InterestSqueeze Risk
Short % of Float?21.99%Squeeze Risk
Short Interest?11.4M
Days to Cover?12.9
Free Float52.0M
Avg Daily Volume889.8K
Settlement Date2026-08-14
Financial Health
Current Ratio?12.90Strong
Quick Ratio?12.90Strong
Cash Ratio?12.57Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?3.07FAIR▾
Peers100
S&P55
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-4.3CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-59.1%WEAK▾
S&P3
ROA?-54.6%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-37810861
Enterprise Value?$400.5M
Fundamentals ratios updated end of day